drugset / Trial / NCT01188304
A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with aspirin on renal function, renin-angiotensin system and platelet aggregation in healthy volunteers. Volunteers will be randomized to receive daily doses of aleglitazar or placebo in combination with aspirin. The anticipated time on study drug is 5 weeks.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aleglitazar | Small molecule | 150 ug | — |
| Background | Aspirin | Small molecule | 325 mg | — |
Indications
No indication recorded.